Nonsteroidal anti-inflammatory drugs (NSAIDs) including sulindac sulfide are known to exert cancer chemopreventative activity in a range of cell lines. This activity has been shown to involve the upregulation of the cyclindependent kinase inhibitor p21
Prostate cancer is a leading cause of cancer-related deaths among men and is difficult to treat with conventional therapies. The identification of targets to prevent prostate carcinogenesis is an alternative approach, which may prove to be effective in lowering the burden of this disease. One such group of targets is the peroxisome proliferator-activated receptors (PPARs). PPARs are members of the Class II nuclear receptor superfamily (Mangelsdorf et al., 1995) which includes a number of other hormone receptors, forming heterodimers with RXR upon activation. Since their discovery, PPARs have been well established as master regulators of adipogenesis (Morrison and Farmer, 1999) and lipid homeostasis (Tontonoz et al., 1994) . PPARg is expressed in prostate cancer cell lines and activation of PPARg within these cell lines has been shown to result in growth inhibition (Mueller et al., 2000) . In contrast to PPARg, the role of ubiquitously expressed PPARd in regulating the growth of human prostate cells is a novel area of research. However, we have recently shown that PPARd agonists have a pro-proliferative effect on human prostate cancer cells (Stephen et al., 2004) . From these data, it appears that PPARg and PPARd have opposing roles in regulating the growth of human prostate cells.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of compounds possessing both anti-inflammatory and analgesic properties. NSAIDs have been shown to suppress colorectal carcinogenesis in both animal models and humans (Smalley and DuBois, 1997) . The NSAID sulindac has the ability to upregulate p21 WAF1/CIP1 expression in colon carcinoma cell lines (Goldberg et al., 1996) . Similarly when p21 WAF1/CIP1 is inactivated in APC min/ þ mice, sulindac sulfide no longer has the ability to lower the number of intestinal tumours (Yang et al., 2001) , indicating that p21 WAF1/CIP1 is an absolute requirement for the anticancer effects of sulindac sulfide.
Several NSAIDs including indomethacin, fenoprofen, flufenamic acid and ibuprofen have been shown to activate PPARg at concentrations of 100 mM (Lehmann et al., 1997) . The NSAID diclofenac can also bind to PPARg at nanomolar concentrations, in this case resulting in an antagonistic interaction (Adamson et al., 2002) . The activity of PPARd is inhibited by sulindac sulfide which has been shown to prevent PPARd/RXR heterodimers from binding to their recognition sequences (He et al., 1999) . Since sulindac sulfide can activate PPARg (Wick et al., 2002) and inhibit PPARd (He et al., 1999) , we hypothesized that the growth inhibitory effects of this compound may be mediated by p21 WAF1/CIP1 upregulation through a dual pathway involving PPARg activation and PPARd repression.
Previous studies into the role of PPARs in proliferation have been performed using highly transformed cancer cell lines. In order to assess the action of sulindac sulfide on PPARs in precancerous cells an immortalized cell line (PNT1A) derived from normal human prostatic epithelium (Cussenot et al., 1991) was utilized as a model of premalignant disease.
Although sulindac sulfide has been studied as a PPARg agonist and a PPARd antagonist in separate cellular contexts, we wished to determine the ability of sulindac sulfide to mediate both of these effects in PNT1A cells. We, therefore, examined the effect of sulindac sulfide on PPAR response elements (PPREs). By transfecting expression vectors encoding either PPARg or PPARd, we were able to ascertain the effects of sulindac sulfide on the activity of each receptor. Figure 1a shows that a known PPARg agonist, rosiglitazone (1 mM) resulted in the activation of transcription from the PPAR target gene liver fatty acid binding protein (DR1) 4-TK-GL3 (LFABP) containing a PPRE reporter construct by approximately 30-fold (***Po0.001). Activation of LFABP is dependent on both additional PPARg expression vector and rosiglitazone. Figure 1b shows that a known PPARd agonist, GW501516 (10 nM) activated PPARd by approximately 3.5-fold (***Po0.001) and this effect was also dependent upon both additional PPARd expression vector and GW501516. Depending on whether PPARg or PPARd was exogenously introduced sulindac sulfide acted as a PPARg agonist activating transcription from the LFABP reporter construct by greater than 10-fold (***Po0.001) ( Figure 1c ) and a PPARd antagonist, repressing transcription from the LFABP reporter construct by approximately 75% (Figure 1d ). In the presence of exogenous PPARg, sulindac sulfide activated PPARg to the same extent as rosiglitazone (***Po0.001) and no synergistic effect was observed (Figure 1e ). In the presence of exogenous PPARd, sulindac sulfide was able to repress GW501516 activation of PPARd (**Po0.01) (Figure 1f) .
To determine what extent sulindac sulfide-mediated PNT1A growth inhibition is dependent on PPARg and PPARd, we utilized siRNA technology to deplete cells of PPARg and PPARd mRNA. In these experiments, we were able to reduce levels of PPARg mRNA by in excess of 90% (***Po0.001) (Figure 2a ) and protein to a lesser extent (Figure 2b) and PPARd mRNA by greater than Figure 2 Sulindac sulfide maintains its growth inhibitory effects in the absence of PPARd but not PPARg and PPARg is required for sulindac sulfide-induced p21 WAF1/CIP1 upregulation. Cells were transfected with SMARTpool siRNA duplexes (5 nM) (Dharmacon) of either PPARg: AGACTCAGCTCTACAATAA GAAGTTCAATGCACTGGAA AAGTAACTCTCCTCAAATA GCATTTC TACTCCACATTA, PPARd: GAGCGCAGCTGCAAGATTC GCATGAAGCTGGAGT ACGA GGAAGCAGTTGGTGAATGG GCTGCAAGATTCAGAAGAA or a nonspecific scrambled oligo control. After 48 h cells were lysed and RNA was extracted using an RNeasy s mini kit (Qiagen). cDNA was synthesized using standard reverse transcription PCR techniques. Steady-state levels of mRNA encoding PPARg and PPARd were determined by real time quantitative PCR as previously described (Young et al., 2002) . Western blotting was performed using standard techniques performed on either 10% glycerol gels (PPARg) or 10% SDS-PAGE gels (PPARd). The primary antibodies used were as follows: antirabbit raised against the AB domain of human PPARg (1 : 2500). PPARd NUC-1 (1 : 500) (Vosper et al., 2001) . b-actin anti-goat (1 : 2000) (Santa Cruz). PPARg (a) mRNA ***Po0.001 and (b) protein levels are reduced after siRNA introduction, as are PPARd (c) mRNA ***Po0.001 and (d) protein levels when compared against the nonspecific (NS) control. The siRNA experiment was carried out as before and after the second round of siRNA cells were treated with either 0.1% DMSO or sulindac sulfide (150 mM) (SS). The measurement of cell numbers was performed as described (Stephen et al., 2004) . NS siRNA-treated cells are responsive to the growth inhibitory effects of sulindac sulfide, **Po0.01, as are PPARd siRNA-treated cells **Po0.01. (e) The proliferation of sulindac sulfide-treated PPARg siRNA compared to DMSO-treated PPARg siRNA PNT1A cells is not significantly different P>0.05. The expression of p21 WAF1/CIP1 mRNA and protein was also carried out after NS and PPARg siRNA and sulindac sulfide treatment. Analysis for p21 WAF1/CIP1 mRNA was carried out with the following forward, reverse primers and probe: F: 5 0 -GACTCTCAGGGTCGAAAACGG-3 0 , R: 5 0 -GCGGATTAGGGCTTCCTCTT-3 0 , P: CTACCACTCCAAACGCCGCT GATCT. Western blotting was performed on 12% SDS-PAGE gels, using the primary antibody p21 WAF1/CIP1 mouse monoclonal (1 : 1000) (Fredersdorf et al., 1996) (Figure 2c ) and protein, again to a lesser extent (Figure 2d ). siRNA transfected cells were then treated with sulindac sulfide. Cells that had been transfected with nonspecific sequences underwent sulindac sulfide-mediated growth inhibition by approximately 70% (**Po0.01), as did PPARd-depleted cells (**Po0.01), which initially would imply that PPARd suppression is not required for the response to sulindac sulfide. Conversely, depletion of PPARg by siRNA virtually abolished the growth inhibitory effects of sulindac sulfide and these cells did not undergo any significant growth inhibition compared to the DMSOtreated control (P>0.5) (Figure 2e ). We then explored the hypothesis that PPARg has a role in the upregulation of p21 WAF1/CIP1 by sulindac sulfide. Cells transfected with nonspecific control siRNA demonstrated sulindac sulfide-mediated p21 WAF1/CIP1 mRNA upregulation by approximately threefold (**Po0.01) (Figure 2f ). This was reflected in p21 WAF1/CIP1 protein upregulation (Figure 2g) . However, the depletion of PPARg in these cells resulted in the loss of sulindac sulfide-mediated p21 WAF1/CIP1 mRNA (P>0.05) ( Figure 2h ) and protein ( Figure 2i ) upregulation, which remained unaltered relative to the DMSO-treated control. This supports the novel hypothesis that PPARg activation by sulindac sulfide is required for p21 WAF1/CIP1 -mediated growth inhibition.
In order to dissect the role of PPARd antagonism in mediating sulindac sulfide growth inhibition we overexpressed PPARd protein by 3.8-fold (Figure 3a) . The moderate overexpression of PPARd rendered cells approximately 40% more resilient to sulindac sulfideinduced growth inhibition (***Po0.001) (Figure 3b ). The overexpression of PPARd also dramatically reduced the capability of cells to upregulate p21 WAF1/CIP1 following sulindac sulfide treatment. Cells transfected with pCLDN vector alone underwent p21 WAF1/CIP1 mRNA upregulation by more than fivefold (**Po0.01) (Figure 3c ), which was also reflected in strong p21 WAF1/CIP1 protein upregulation (Figure 3d) . Conversely, cells transfected with pCLDN PPARd failed to show any significant increases in p21 WAF1/CIP1 mRNA (P>0.5) (Figure 3e ) and displayed greatly reduced p21 WAF1/CIP1 protein upregulation (Figure 3f ).
Daily use of NSAIDs has been associated with a reduction in prostate cancer risk (Nelson and Harris, 2000) . Initially, it was believed that the antineoplastic activity of NSAIDs was mediated by their ability to bind to and inhibit cyclooxygenase (COX) enzymes. COX enzymes are responsible for mediating the conversion of arachidonic acid into prostaglandins. Since particular types of prostaglandins have been shown to promote carcinogenesis (Lupulescu, 1978) it seemed logical that this hypothesis was correct. However, it has since been shown that NSAIDs can inhibit growth and cause the death of cells not expressing COX enzymes (Hanif et al., 1996) . Furthermore, the NSAID derivative sulindac sulfone is unable to inhibit COX but retains the ability to inhibit tumour growth (Piazza et al., 1997) hence other pathways may also play a role. Other groups have confirmed sulindac sulfide as a PPARg agonist and also proposed it as an important factor of COX independent inhibition of lung cancer cell growth (Wick et al., 2002) . Our experiments extrapolate from this work functionally implicating PPARg in sulindac sulfide-mediated growth inhibition. We also further demonstrate that this is achieved by p21 WAF1/CIP1 upregulation, a previously established mechanism of PPARg ligand-mediated growth inhibition (Hong et al., 2004) .
Previous studies have also implicated PPARd in mediating the anticancer effects of sulindac sulfide. He et al. (1999) proposed an antagonistic effect of sulindac sulfide on PPARd, which they initially believed to be responsible for the induction of apoptosis in colon cancer cells. However, after depleting colon cancer cells WAF1/CIP1 protein in PPARd transfected cells treated with sulindac sulfide is also not strongly upregulated compared to DMSO treated alone of PPARd, the authors observed that sulindac sulfidemediated apoptosis still occurred and concluded PPARd repression was not responsible for this effect (Park et al., 2001) . Similarly, our experiments using siRNA of PPARd failed to inhibit sulindac sulfide-mediated growth inhibition. However, depletion of PPARd by siRNA was sufficient to slow the growth of the cells (data not shown) consistent with that previously observed with deletion of the PPARd gene (Park et al., 2001) . This implies that maximum growth inhibition from interrupting PPARd signalling was achieved via PPARd depletion, thus we considered a gain of function approach as more amenable to study PPARd antagonism. Moderate PPARd overexpression partially protected cells from sulindac sulfide-mediated growth inhibition and also virtually abolished sulindac sulfidemediated p21 WAF1/CIP1 upregulation. Importantly, PPARd has been shown to be overexpressed in some cancers (He et al., 1999) and (Gupta et al., 2000) . Together, these results offer insight into the observed efficacy of NSAIDs in cancer chemoprevention and also reveal a mechanism by which advanced cancers may be less sensitive to such compounds.
